Electronic and Lab Pre-screening of New Rheumatology Patients With Rheumatoid Arthritis

Electronic and Lab Pre-screening of New Rheumatology Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03843619

Enrollment

200

Registered

2019-02-18

Start date

2019-02-28

Completion date

2022-03-31

Last updated

2019-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Arthritis, Rheumatoid Arthritis

Brief summary

By forming the foundation of a delivery system that integrates primary care (PC) and rheumatology, this initiative strives to strengthen the roles of both primary care and rheumatology practices as they co-manage patients in a quality care delivery system. Importantly, it strives to fill an unmet need, the rapid evaluation by Primary Care providers; the appropriate and timely referral of inflammatory disease patients to a rheumatologist; and the implementation of early aggressive therapy in the management of patients with rheumatoid arthritis (RA) with tight control. Given the call for improved quality, value, and demonstration of results\[1\], this initiative uses the tenets of National Center for Quality Assurance's Patient Centered Specialty Program\[1\] (PCSP) and it successfully masters and streamlines coordination of care.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* First ever referral to a rheumatologist.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
To increase referral efficiencies through an electronic system to decrease the timeline prior	One year enrollment period	Mean and median time (in days) to the first rheumatology visit from PCP referral for both cohorts

Secondary

Measure	Time frame	Description
To assess difference in disease activity progression using Clinical Disease Activity Index (CDAI) at both 12 and 24 months.	One year enrollment period with two year follow-up period.	The change in CDAI score from baseline at 1 and 2 years. CDAI uses a scale of 0 - 60 where scores less than 2.8 are considered remission, 2.9 - 10.0 are low disease activity, 10.1 - 22.0 are moderate disease activity, and 22.1 or higher are high disease activity.
To assess difference in disease activity progression using Routine Assessment of Patient Index Data (RAPID3) at both 12 and 24 months.	One year enrollment period with two year follow-up period.	The change in RAPID3 score from baseline at 1 and 2 years. RAPID3 uses a scale of 0 - 30 where scores less than 3.1 are considered remission, 3.1 - 6.0 are low disease activity, 6.1 - 12.0 are moderate disease activity, and 12.1 or higher are high disease activity.
To assess radiographic progression using sharp scores in the electronically referred cohorts versus the traditional cohort.	One year enrollment period with two year follow-up period.	The change in sharp scores from baseline at 1 and 2 years.

Outcome results